Study finds new obesity drugs may cut asthma attacks by 40%

A recent study has found that semaglutide, a medication used to treat diabetes and support weight loss, was associated with a roughly 40% reduction in asthma attacks among certain patients.

Researchers suggested that GLP-1 receptor agonists, a class of weight-loss drugs, may offer benefits beyond weight and blood sugar control, according to Asharq.

The findings were presented at the annual meeting of the European Respiratory Society in Spain. The study concluded that semaglutide was also linked to a 20% reduction in exacerbations of chronic obstructive pulmonary disease (COPD). However, the researchers emphasized that their analysis was based on patient medical records rather than a randomized clinical trial, so it cannot be confirmed that the drug itself directly caused the reduction in respiratory episodes.